These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21752394)

  • 1. Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels.
    Khan A; Khan SR; Hobus J; Faucett J; Mehra V; Giller EL; Rudolph RL
    J Psychiatr Res; 2011 Nov; 45(11):1489-96. PubMed ID: 21752394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin C as an adjuvant for treating major depressive disorder and suicidal behavior, a randomized placebo-controlled clinical trial.
    Sahraian A; Ghanizadeh A; Kazemeini F
    Trials; 2015 Mar; 16():94. PubMed ID: 25873303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
    Canuso CM; Singh JB; Fedgchin M; Alphs L; Lane R; Lim P; Pinter C; Hough D; Sanacora G; Manji H; Drevets WC
    Am J Psychiatry; 2018 Jul; 175(7):620-630. PubMed ID: 29656663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
    Wade AG; Crawford GM; Nemeroff CB; Schatzberg AF; Schlaepfer T; McConnachie A; Haazen L; Buntinx E
    Psychol Med; 2011 Oct; 41(10):2089-97. PubMed ID: 21349239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Citalopram and suicidality in adult major depression and anxiety disorders.
    Pedersen AG
    Nord J Psychiatry; 2006; 60(5):392-9. PubMed ID: 17038305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.
    von Knorring AL; Olsson GI; Thomsen PH; Lemming OM; Hultén A
    J Clin Psychopharmacol; 2006 Jun; 26(3):311-5. PubMed ID: 16702897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
    Huang ML; Luo BY; Hu JB; Wang SS; Zhou WH; Wei N; Hu SH; Xu Y
    Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does lithium reduce acute suicidal ideation and behavior? A protocol for a randomized, placebo-controlled multicenter trial of lithium plus Treatment As Usual (TAU) in patients with suicidal major depressive episode.
    Lewitzka U; Jabs B; Fülle M; Holthoff V; Juckel G; Uhl I; Kittel-Schneider S; Reif A; Reif-Leonhard C; Gruber O; Djawid B; Goodday S; Haussmann R; Pfennig A; Ritter P; Conell J; Severus E; Bauer M
    BMC Psychiatry; 2015 May; 15():117. PubMed ID: 25986590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
    Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
    J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression.
    Bschor T; Uhr M; Baethge C; Lewitzka U; Ising M; Erbe S; Winkelmann P; Ritter D
    J Clin Psychopharmacol; 2013 Feb; 33(1):38-44. PubMed ID: 23277245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
    Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression.
    Bech P; Tanghøj P; Cialdella P; Andersen HF; Pedersen AG
    Int J Neuropsychopharmacol; 2004 Sep; 7(3):283-90. PubMed ID: 15320956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
    Ionescu DF; Fu DJ; Qiu X; Lane R; Lim P; Kasper S; Hough D; Drevets WC; Manji H; Canuso CM
    Int J Neuropsychopharmacol; 2021 Jan; 24(1):22-31. PubMed ID: 32861217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lithium Augmentation Versus Citalopram Combination in Imipramine-Resistant Major Depression: A 10-Week Randomized Open-Label Study.
    Navarro V; Boulahfa I; Obach A; Jerez D; Diaz-Ricart M; Gastó C; Guarch J
    J Clin Psychopharmacol; 2019; 39(3):254-257. PubMed ID: 30925498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.